Qualasept Pharmaxo Holdings

What Qualasept Pharmaxo Holdings does

Qualasept Pharmaxo Holdings, operating as Pharmaxo Group, is a UK-based privately held holding company registered in England and Wales that operates two wholly-owned subsidiaries: Bath ASU and Pharmaxo Healthcare. Bath ASU is a pharmaceutical specials manufacturer producing thousands of aseptic products per week, including patient-specific chemotherapy, dose-banded batch chemotherapy, central intravenous additive products, and patient-controlled analgesia products, supplying customers and patients nationwide from its Corsham, UK headquarters. Pharmaxo Healthcare is a specialist pharmacy provider and clinical homecare company that delivers high-tech treatments directly to patients in their own homes and in community-based settings, working with the NHS, pharmaceutical companies, private medical providers, and self-funding patients.

The business model combines fee-based contract manufacturing (aseptic specials supplied to NHS trusts and pharmaceutical companies) with clinical homecare service delivery funded through NHS commissioning, private medical-provider contracts, and self-pay channels. Distribution is direct to enterprise (NHS trusts, pharmaceutical companies, private medical providers) and direct-to-patient for homecare services, all within a single-country UK footprint. The underlying technology base is centered on regulated aseptic manufacturing processes, with recent investment (September 2025) in MALDI-TOF analytical equipment to support quality validation, and on clinical homecare logistics for at-home treatment administration.

The company's competitive positioning rests on a regulatory moat derived from MHRA-licensed aseptic manufacturing, an established nationwide clinical homecare network, and academic partnerships supporting stability research across the medicine supply chain. The NHS is both the largest customer and a strategic capacity partner, with the Queen's Award for Enterprise (2019) providing reputational validation. Pricing is not publicly disclosed, and no external funding, M&A, or parent-company ownership is evidenced — the group operates as an independent private entity.

Name

Qualasept Pharmaxo Holdings

Legal name

Pharmaxo

Website

https://qphl.co

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Qualasept Pharmaxo Holdings, operating as Pharmaxo Group, is a UK-based private holding company with two wholly-owned subsidiaries: Bath ASU (pharmaceutical aseptic manufacturing) and Pharmaxo Healthcare (clinical homecare), serving the NHS, pharmaceutical companies, private providers, and self-funding patients across the UK.

Ownership category

akta.pro rank

Product category

Pharmaceutical Aseptic Manufacturing and Clinical Homecare

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG)

akta.pro secondary industries

In-Home Infusion Pharmacy Support & Coordination (HSABALAH), Injectables & Specialty Medication Support (e.g., insulin, biologics) (HSABALAG), Hospital & Health-System Pharmacies (Inpatient/Outpatient) (HLAFALAB)

Keywords

• Aseptic pharmaceutical manufacturing
• Clinical homecare services
• Chemotherapy compounding
• Specials manufacturing
• Homecare pharmacy

Headquarters

HQ city

Corsham

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Distribution channels2 records

Marketing channels2 records

Core offering

Qualasept Pharmaxo Holdings operates the Pharmaxo Group, a UK-based holding company providing pharmaceutical aseptic manufacturing and clinical homecare services. Through its Bath ASU subsidiary it produces patient-specific chemotherapy, dose-banded batch chemotherapy, central intravenous additive products, and patient-controlled analgesia; through Pharmaxo Healthcare it delivers high-tech treatments to patients in their homes and community settings for the NHS, pharmaceutical companies, private providers, and self-funding patients.

Product overview

Pharmaxo Group operates as a holding company with two main subsidiaries providing pharmaceutical and healthcare services. Bath ASU focuses on pharmaceutical aseptic manufacturing (patient-specific chemotherapy, batch chemotherapy, IV additives, pain management products), while Pharmaxo Healthcare provides clinical homecare and specialist pharmacy services delivering high-tech treatments to patients in their homes and community settings. Together, the manufacturing and healthcare divisions provide the NHS with extra capacity to ensure patients receive critical treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• Bath ASU Aseptic Manufacturing Services Aseptic manufacturing service producing patient-specific chemotherapy, dose-banded batch chemotherapy, central intravenous additive service (CIVAS) products, and patient-controlled analgesia for NHS trusts, pharmaceutical companies, and private medical providers.
• Pharmaxo Healthcare Clinical Homecare Services Specialist pharmacy and clinical homecare service delivering high-tech treatments to patients in their own homes and community-based settings, serving NHS, pharmaceutical companies, private medical providers, and self-funding patients.

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Academic InstitutionscoreStrategic or Co-development PartnerPharmaxo Group maintains strong connections to academia for pioneering stability research. Scientists and R&D teams work collaboratively to improve value and safety throughout the medicine supply chain.
• NHScoreStrategic or Co-development PartnerPharmaxo manufacturing and healthcare divisions provide the NHS with extra capacity, ensuring patients receive critical treatments on time and in comfortable environments. Primary customer partner for both Bath ASU and Pharmaxo Healthcare services.

Scale indicators1 record

Expansion highlights4 records

Market position

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qualasept Pharmaxo Holdings